doi: 10.1186/s12964-025-02447-x 73 ZhangYSwandaRVNieLLiuXWangCLeeHet al
10.1016/j.lfs.2010.12.019 74 PangC.ShengY
Understanding the possible risks and undergoing treatment under supervision can help improve overall safety
Patients have reported patchy skin color (where different areas of the skin have different tones) and premature graying of hair due to the significant reduction of melanin
89 COMPARISON OF RECURRENCE PREDICTION MODELS AND IMBRAVE 050 CRITERIA TO SELECT PATIENTS FOR ADJUVANT IMMUNOTHERAPY AFTER CURATIVE RESECTION OF HEPATOCELLULAR CARCINOMA I-Cheng Lee 1,2 , Hao-Cyuan Chu 2 , Shinn-Ying Ho 2 , Gar-Yang Chau 3 , Ming-Chih Hou 1 and Yi-Hsiang Huang 1,2 , (1)Taipei Veterans General Hospital, (2)National Yang Ming Chiao Tung University, (3)Taipei Veterans General Hospital Department Surgery Background: The IMbrave 050 trial recently demonstrated positive results of the adjuvant atezolizumab plus bevacizumab therapy for hepatocellular carcinoma (HCC) patients at high-risk of recurrence after curative treatment
doi: 10.1073/pnas.1603244113 22 LiCDengXZhangWXieXConradMLiuYet al
